Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2535-2542

  Stingl, Julia Carolin ^a   Parmar, Sumit ^a   Huber Wechselberger, Ariana ^b   Kainz, Alexander ^c   Renner, Wilfried ^d   Seeringer, Angela ^a   Brockmller, Jrgen ^e   Langsenlehner, Uwe ^f   Krippl, Peter ^c   Haschke Becher, Elisabeth ^b  

^a UNIVERSITY OF ULM   (Germany)

^b ELISABETHINEN HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f Internal Outpatient Department   (Austria)

Author keywords

Chemotherapy; Cytochrome P 450 2D6; Estrogen receptor positive breast cancer; Tamoxifen

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTOCHROME P450 2D6; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; AGED; AUSTRIA; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AUSTRIA; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 77958115704     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.518304     Document Type: Article

References (24)

1. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen bio-transformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-18
2. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74
3. Lash TL, Lien EA, Sorensen HT, et al. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009;10:825-33
4. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009;9:576-86
5. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-36
6. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93
7. Bijl MJ, Van Schaik RH, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009;118:125-30
8. Ramon YCT, Altes A, Pare L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010;119:33-8
9. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008;99:995-9
10. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21
11. Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008; 14:5913-18
12. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58
13. Okishiro M, Taguchi T, Jin Kim S, et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009;115:952-61
14. Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7
15. Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284-90
16. Goetz M, Berry D, Klein T, Consortium atITP. Cancer Res 2009;69(Suppl.) Abstract 33
17. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9
18. Lim YC, Li L, Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318:503-12
19. Higgins MJ, Rae JM, Flockhart DA, et al. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw 2009; 7:203-13
20. Langsenlehner U, Wolf G, Langsenlehner T, et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian 'tumor of breast tissue: incidence, genetics, and environmental risk factors' study. Breast Cancer Res Treat 2008;109:297-304
21. Krippl P, Langsenlehner U, Samonigg H, et al. Vascular endothelial growth factor in predicting outcome in breast cancer. Clin Cancer Res 2004; 10:8752-3
22. Brauch H, Murdter TE, Eichelbaum M, et al. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009;55:1770-82
23. Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008;19:1423-9
24. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717